CA2622468A1 - Composition contenant au moins un derive d'acide naphtoique et au moins un compose de type polymere de polyurethane ou des derives de ce compose, procedes de fabrication et utilisations de cette composition - Google Patents

Composition contenant au moins un derive d'acide naphtoique et au moins un compose de type polymere de polyurethane ou des derives de ce compose, procedes de fabrication et utilisations de cette composition Download PDF

Info

Publication number: CA2622468A1
Authority: CA; Canada
Prior art keywords: naphthoic acid; composition according; acne; composition; adapalene
Prior art date: 2005-09-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002622468A

Other languages

English (en)

Inventor

Claire Mallard

Eve Ferrara

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Galderma Research and Development SNC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-16

Filing date

2006-09-15

Publication date

2007-03-22

2005-09-16 Priority claimed from FR0509493A external-priority patent/FR2890861B1/fr

2006-09-15 Application filed by Individual filed Critical Individual

2007-03-22 Publication of CA2622468A1 publication Critical patent/CA2622468A1/fr

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 242
229920000642 polymer Polymers 0.000 title claims abstract description 57
229920002635 polyurethane Polymers 0.000 title claims abstract description 52
239000004814 polyurethane Substances 0.000 title claims abstract description 52
150000005209 naphthoic acids Chemical class 0.000 title claims abstract description 42
150000001875 compounds Chemical class 0.000 title claims abstract description 34
238000002360 preparation method Methods 0.000 title claims description 21
239000002537 cosmetic Substances 0.000 claims abstract description 8
LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 152
206010000496 acne Diseases 0.000 claims description 67
208000002874 Acne Vulgaris Diseases 0.000 claims description 61
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 49
239000012071 phase Substances 0.000 claims description 36
239000008213 purified water Substances 0.000 claims description 30
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 27
239000006210 lotion Substances 0.000 claims description 23
239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 22
229960002216 methylparaben Drugs 0.000 claims description 22
239000003349 gelling agent Substances 0.000 claims description 21
239000003995 emulsifying agent Substances 0.000 claims description 20
239000000839 emulsion Substances 0.000 claims description 19
239000003755 preservative agent Substances 0.000 claims description 16
239000002738 chelating agent Substances 0.000 claims description 14
239000000126 substance Substances 0.000 claims description 14
239000000080 wetting agent Substances 0.000 claims description 14
239000008346 aqueous phase Substances 0.000 claims description 13
239000006071 cream Substances 0.000 claims description 13
239000006185 dispersion Substances 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 12
238000003756 stirring Methods 0.000 claims description 12
239000003974 emollient agent Substances 0.000 claims description 9
239000007788 liquid Substances 0.000 claims description 9
238000010438 heat treatment Methods 0.000 claims description 7
235000013336 milk Nutrition 0.000 claims description 7
239000008267 milk Substances 0.000 claims description 7
210000004080 milk Anatomy 0.000 claims description 7
239000003921 oil Substances 0.000 claims description 7
239000007787 solid Substances 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 6
238000004945 emulsification Methods 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
239000000375 suspending agent Substances 0.000 claims description 6
206010000501 Acne conglobata Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
230000003780 keratinization Effects 0.000 claims description 4
238000006386 neutralization reaction Methods 0.000 claims description 4
239000007764 o/w emulsion Substances 0.000 claims description 4
229920001296 polysiloxane Polymers 0.000 claims description 4
201000004700 rosacea Diseases 0.000 claims description 4
240000006661 Serenoa repens Species 0.000 claims description 3
235000005318 Serenoa repens Nutrition 0.000 claims description 3
235000021028 berry Nutrition 0.000 claims description 3
230000024245 cell differentiation Effects 0.000 claims description 3
230000004663 cell proliferation Effects 0.000 claims description 3
239000000284 extract Substances 0.000 claims description 3
238000000265 homogenisation Methods 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
230000001338 necrotic effect Effects 0.000 claims description 3
230000000306 recurrent effect Effects 0.000 claims description 3
239000010018 saw palmetto extract Substances 0.000 claims description 3
TVIKMHRYESWHCR-UHFFFAOYSA-N 6-[3-(1-adamantyl)-4-decoxyphenyl]naphthalene-2-carboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OCCCCCCCCCC)=CC=C21 TVIKMHRYESWHCR-UHFFFAOYSA-N 0.000 claims description 2
BCLMUIMQCLRLNV-UHFFFAOYSA-N 6-[3-(1-adamantyl)-4-hexoxyphenyl]naphthalene-2-carboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OCCCCCC)=CC=C21 BCLMUIMQCLRLNV-UHFFFAOYSA-N 0.000 claims description 2
LDGIHZJOIQSHPB-UHFFFAOYSA-N CD437 Chemical compound C1C(C2)CC(C3)CC2CC13C1=CC(C2=CC3=CC=C(C=C3C=C2)C(=O)O)=CC=C1O LDGIHZJOIQSHPB-UHFFFAOYSA-N 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
230000032683 aging Effects 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 2
239000004530 micro-emulsion Substances 0.000 claims description 2
239000003094 microcapsule Substances 0.000 claims description 2
239000011859 microparticle Substances 0.000 claims description 2
230000001105 regulatory effect Effects 0.000 claims description 2
239000000725 suspension Substances 0.000 claims description 2
230000000699 topical effect Effects 0.000 abstract description 20
229960002916 adapalene Drugs 0.000 description 138
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 105
238000009472 formulation Methods 0.000 description 98
239000000499 gel Substances 0.000 description 76
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
239000000902 placebo Substances 0.000 description 48
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 43
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 42
229940068196 placebo Drugs 0.000 description 41
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 40
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 31
238000000034 method Methods 0.000 description 30
210000003491 skin Anatomy 0.000 description 30
239000003981 vehicle Substances 0.000 description 22
239000000470 constituent Substances 0.000 description 19
-1 especially Chemical class 0.000 description 18
229920001983 poloxamer Polymers 0.000 description 18
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 17
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 17
229960003415 propylparaben Drugs 0.000 description 17
238000012360 testing method Methods 0.000 description 16
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 15
239000002085 irritant Substances 0.000 description 15
229920002125 Sokalan® Polymers 0.000 description 14
231100000021 irritant Toxicity 0.000 description 13
239000002736 nonionic surfactant Substances 0.000 description 13
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 11
210000002615 epidermis Anatomy 0.000 description 11
238000003556 assay Methods 0.000 description 10
241000699670 Mus sp. Species 0.000 description 9
239000013543 active substance Substances 0.000 description 9
BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 8
229960005323 phenoxyethanol Drugs 0.000 description 8
230000036572 transepidermal water loss Effects 0.000 description 8
NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 7
JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
229940075510 carbopol 981 Drugs 0.000 description 6
230000002995 comedolytic effect Effects 0.000 description 6
STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
230000035515 penetration Effects 0.000 description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
229920000053 polysorbate 80 Polymers 0.000 description 6
239000013641 positive control Substances 0.000 description 6
210000000434 stratum corneum Anatomy 0.000 description 6
239000004094 surface-active agent Substances 0.000 description 6
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 5
238000011725 BALB/c mouse Methods 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
238000012801 analytical assay Methods 0.000 description 5
210000004207 dermis Anatomy 0.000 description 5
230000001804 emulsifying effect Effects 0.000 description 5
239000012530 fluid Substances 0.000 description 5
VMGLLMDIYIPVHX-UHFFFAOYSA-N 1-benzothiophene-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CSC2=C1 VMGLLMDIYIPVHX-UHFFFAOYSA-N 0.000 description 4
ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
210000005069 ears Anatomy 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000007794 irritation Effects 0.000 description 4
229960001727 tretinoin Drugs 0.000 description 4
LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 3
208000032544 Cicatrix Diseases 0.000 description 3
229920003102 Methocel™ E4M Polymers 0.000 description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
239000000654 additive Substances 0.000 description 3
229960000686 benzalkonium chloride Drugs 0.000 description 3
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
231100000241 scar Toxicity 0.000 description 3
230000037387 scars Effects 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 2
VYBLDUKQAWIMMM-UHFFFAOYSA-N 2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1-benzothiophene-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2SC(C=3C=C4C(C)(C)CCC(C4=CC=3)(C)C)=CC2=C1 VYBLDUKQAWIMMM-UHFFFAOYSA-N 0.000 description 2
BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical group CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
229920003091 Methocel™ Polymers 0.000 description 2
240000001307 Myosotis scorpioides Species 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
206010037888 Rash pustular Diseases 0.000 description 2
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
239000010775 animal oil Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical compound C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 description 2
238000001917 fluorescence detection Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229960005280 isotretinoin Drugs 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
229960003330 pentetic acid Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000010773 plant oil Substances 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
208000029561 pustule Diseases 0.000 description 2
238000011002 quantification Methods 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
210000001732 sebaceous gland Anatomy 0.000 description 2
229920002545 silicone oil Polymers 0.000 description 2
230000008591 skin barrier function Effects 0.000 description 2
230000003068 static effect Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 1
UXBIXOXDACBTDG-UHFFFAOYSA-N 1-adamantyl radical Chemical compound C1C(C2)CC3C[C]1CC2C3 UXBIXOXDACBTDG-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
XYTHHAXRVHHXKO-JIUYZRCGSA-N 18-[(2r,3s,4r,5r)-4,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxyoctadecanoic acid;ethanol Chemical compound CCO.COC1O[C@H](CO)[C@@H](OCCCCCCCCCCCCCCCCCC(O)=O)[C@H](O)[C@H]1O XYTHHAXRVHHXKO-JIUYZRCGSA-N 0.000 description 1
229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
208000020154 Acnes Diseases 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
241001440269 Cutina Species 0.000 description 1
XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
229920004511 Dow Corning® 200 Fluid Polymers 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
206010033733 Papule Diseases 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
206010039792 Seborrhoea Diseases 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000005250 alkyl acrylate group Chemical group 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
229960000458 allantoin Drugs 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940058140 avita Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
229960003168 bronopol Drugs 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229940073669 ceteareth 20 Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229940086555 cyclomethicone Drugs 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000035618 desquamation Effects 0.000 description 1
SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
229960001083 diazolidinylurea Drugs 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
229940031578 diisopropyl adipate Drugs 0.000 description 1
229940008099 dimethicone Drugs 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
230000003325 follicular Effects 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
230000008570 general process Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229940075529 glyceryl stearate Drugs 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
229920003111 hydroxyethyl cellulose HHX Polymers 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940100460 peg-100 stearate Drugs 0.000 description 1
229940119519 peg-32 stearate Drugs 0.000 description 1
229940119517 peg-6 stearate Drugs 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000009467 reduction Effects 0.000 description 1
235000020945 retinal Nutrition 0.000 description 1
239000011604 retinal Substances 0.000 description 1
229960003471 retinol Drugs 0.000 description 1
235000020944 retinol Nutrition 0.000 description 1
239000011607 retinol Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
210000002374 sebum Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000003009 skin protective agent Substances 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
RYPYDIHMPGBBJN-UHFFFAOYSA-M sodium;2-methyl-1-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].CC(C)C(S([O-])(=O)=O)NC(=O)C=C RYPYDIHMPGBBJN-UHFFFAOYSA-M 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
150000003445 sucroses Chemical class 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
229960000565 tazarotene Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/87—Polyurethanes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Birds (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Emergency Medicine (AREA)
Gerontology & Geriatric Medicine (AREA)
Inorganic Chemistry (AREA)
Cosmetics (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)
Polyurethanes Or Polyureas (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CA002622468A 2005-09-16 2006-09-15 Composition contenant au moins un derive d'acide naphtoique et au moins un compose de type polymere de polyurethane ou des derives de ce compose, procedes de fabrication et utilisations de cette composition Abandoned CA2622468A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
FR0509493		2005-09-16
FR0509493A FR2890861B1 (fr)	2005-09-16	2005-09-16	Compositions comprenant au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethanes ou des derives de celui-ci, leurs procede de preparation, et leur utilisation
US72527905P	2005-10-12	2005-10-12
US60/725,279		2005-10-12
PCT/IB2006/003852 WO2007031883A2 (fr)	2005-09-16	2006-09-15	Composition contenant au moins un derive d'acide naphtoique et au moins un compose de type polymere de polyurethane ou des derives de ce compose, procedes de fabrication et utilisations de cette composition

Publications (1)

Publication Number	Publication Date
CA2622468A1 true CA2622468A1 (fr)	2007-03-22

Family

ID=37865321

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002622468A Abandoned CA2622468A1 (fr)	2005-09-16	2006-09-15	Composition contenant au moins un derive d'acide naphtoique et au moins un compose de type polymere de polyurethane ou des derives de ce compose, procedes de fabrication et utilisations de cette composition

Country Status (7)

Country	Link
EP (1)	EP1933827A2 (fr)
JP (2)	JP5074401B2 (fr)
AU (1)	AU2006290364B2 (fr)
CA (1)	CA2622468A1 (fr)
MX (1)	MX2008003422A (fr)
RU (1)	RU2421216C2 (fr)
WO (1)	WO2007031883A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7820186B2 (en)	2001-12-21	2010-10-26	Galderma Research & Development	Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
FR2916966B1 (fr) *	2007-06-11	2011-01-14	Galderma Res & Dev	Compositions comprenant au moins un compose retinoide, un compose anti-irritant et du peroxyde de benzoyle, et leurs utilisations
FR2916975B1 (fr) *	2007-06-11	2009-09-04	Galderma Res & Dev	Compositions comprenant au moins un compose retinoide, un compose anti-irritant et du peroxyde de benzoyle, et leurs utilisations
WO2009007341A2 (fr) *	2007-07-06	2009-01-15	Galderma Research & Development	Compositions destinées à l'application topique pour le traitement des troubles de la kératinisation
EP2065032A1 (fr) *	2007-11-27	2009-06-03	Galderma Research & Development	Procédé pour la production de gels d'adapalène
BRPI0819047A2 (pt) *	2007-11-30	2015-05-05	Galderma Res & Dev	"composição, seu processo de preparação e seus usos"
US9463158B2 (en)	2009-06-24	2016-10-11	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
US11684624B2 (en)	2009-06-24	2023-06-27	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
US12138268B2 (en)	2009-06-24	2024-11-12	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
EP2445492B1 (fr) *	2009-06-24	2016-09-28	Strategic Science & Technologies, LLC	Composition topique contenant de l'ibuprofène
JP5521190B2 (ja) *	2009-10-01	2014-06-11	国立大学法人東京工業大学	コラーゲン組成物及びその製造方法
US20130203850A1 (en) *	2010-04-29	2013-08-08	Galderma Research & Development	Method for treating scars with adapalene 0.3%
US20150080352A1 (en) *	2012-03-09	2015-03-19	Bayer Materialscience Llc	Aqueous polyurethane dispersion in the treatment of acne
JPWO2019240290A1 (ja) *	2018-06-16	2021-06-24	ロート製薬株式会社	外用組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE115553T1 (de) *	1987-07-16	1994-12-15	Univ California	Mittel zur steigerung der hautpenetration von pharmakologisch aktiven verbindungen.
JPH061851A (ja) *	1992-06-19	1994-01-11	Toyo Ink Mfg Co Ltd	顔料組成物および水性顔料分散体
US6358541B1 (en) *	2000-05-03	2002-03-19	David S. Goodman	Topical preparation for the treatment of hair loss
EP1485080B1 (fr) *	2002-03-12	2009-05-27	Galderma Research & Development	Emploi d'adapalene pour le traitement de troubles dermatologiques

2006
- 2006-09-15 AU AU2006290364A patent/AU2006290364B2/en active Active
- 2006-09-15 RU RU2008114840/15A patent/RU2421216C2/ru active
- 2006-09-15 EP EP06831837A patent/EP1933827A2/fr not_active Withdrawn
- 2006-09-15 JP JP2008530661A patent/JP5074401B2/ja active Active
- 2006-09-15 MX MX2008003422A patent/MX2008003422A/es active IP Right Grant
- 2006-09-15 CA CA002622468A patent/CA2622468A1/fr not_active Abandoned
- 2006-09-15 WO PCT/IB2006/003852 patent/WO2007031883A2/fr active Application Filing
2012
- 2012-06-20 JP JP2012138489A patent/JP2012184258A/ja active Pending

Also Published As

Publication number	Publication date
EP1933827A2 (fr)	2008-06-25
JP2012184258A (ja)	2012-09-27
RU2008114840A (ru)	2009-10-27
JP2009508843A (ja)	2009-03-05
JP5074401B2 (ja)	2012-11-14
RU2421216C2 (ru)	2011-06-20
MX2008003422A (es)	2008-03-27
WO2007031883A3 (fr)	2007-09-13
WO2007031883A2 (fr)	2007-03-22
AU2006290364A1 (en)	2007-03-22
AU2006290364B2 (en)	2012-07-05

Publication	Publication Date	Title
AU2006290364B2 (en)	2012-07-05	Composition comprising at least one naphthoic acid derivative and at least one compound of polyurethane polymer type or derivatives thereof, preparation processes therefor and uses thereof
US8709392B2 (en)	2014-04-29	Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers
US8568704B2 (en)	2013-10-29	Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer
US20090191245A1 (en)	2009-07-30	Reduced-irritant dermatological compositions comprising at least one naphthoic acid compound and benzoyl peroxide and treatment of keratinization disorders therewith
US20150342920A1 (en)	2015-12-03	Dermatological compositions comprising at least one retinoid compound, an anti-irritant compound and benzoyl peroxide
AU2005321158A1 (en)	2006-07-06	Composition comprising solubilized adapalene with cyclodextrins
US20130039995A1 (en)	2013-02-14	Dermatological compositions comprising at least one reinoid compound, an anti-irritant compound and benzoyl peroxide
US8937098B2 (en)	2015-01-20	Dermatological compositions comprising at least one naphthoic acid compound and at least one film-forming agent and treatment of keratinization disorders therewith

Legal Events

Date	Code	Title	Description
2011-09-13	EEER	Examination request
2015-08-18	FZDE	Dead	Effective date: 20150623